



Supramolecular Anti-Infectives

Guest Editor:

**Prof. Dr. Anthony William
Coleman**

LMI CNRS UMR 5615, Université
Lyon 1, 69622 Villeurbanne,
France

Deadline for manuscript
submissions:

closed (30 June 2020)

Message from the Guest Editor

For this Special Issue, it is best to first define the title. Regarding “Supramolecular”, we will consider any molecular assembly, other than colloidal systems, that is held together by non-covalent bonding as being supramolecular. Anti-infectives can be defined as Active Pharmaceutical Ingredients that act against invasive disease causing agents. Thus, we will be happy to see papers on anti-virals, anti-bacterials, and fungicidal and anti-parasitic agents, but also on epigenetic agents. Supramolecular systems can act as excipients; co-crystal formers; API transporters; or, more interestingly, as APIs themselves.

In terms of the study, all aspects of the subject are welcome, from structural studies of supramolecular API complexes through biochemical studies to clinical studies. Subjects at the edge of the definitions are particularly welcomed; these could include new technologies such as 3D printing as long as there is a supramolecular anti-infective involved.

Keywords: Active Pharmaceutical Ingredients; Anti-virals; anti-bacterials; fungicidal agents; anti-parasitic agents; Epigenetic agents; Supramolecular systems, excipients





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi